Global Dyspnea Treatment MarketThe global dyspnea treatment market, valued at USD 5.90 billion in 2022, is expected to experience robust growth, projected to reach approximately USD 12.3 billion by ...

Any Australian who has filled a prescription at the chemist will have been asked if they want a branded product or the generic version. And with consumers looking to cut costs wherever they can ...

The U.S. Centers for Medicare & Medicaid Services (CMS) has released a preliminary list of 101 generic drugs that would ... lithium and albuterol asthma inhalers, as well as drugs for high ...

U.S. researchers have detected microplastic particles in air exhaled by wild bottlenose dolphins, suggesting that inhalation may be a relevant route of exposure to these potentially harmful ...

The Biden administration has reformed Medicare, gone after bogus drug patents and pushed pharmaceutical companies to reduce inhaler costs for patients. “Climate-friendly inhalers” could jeopardize ...

Similarly, AstraZeneca’s blockbuster drug Symbicort is only now facing a generic competitor, nearly 20 years after its 2006 launch. The inhaler has been widely prescribed because it contains a ...

Vaccines are an essential part of global efforts to reduce AMR as they prevent infections, reduce the use and overuse of antimicrobials, and slow the emergence and spread of drug-resistant pathogens.

The list, comprising 101 generic drugs, includes common prescriptions like penicillin, metformin, and lithium, as well as asthma inhalers like albuterol. Notably, these drugs will not require prior ...

in response to President Joe Biden’s executive order to lower prescription drug costs. The CMS has compiled a sample list of 272 medications, including various pills, ointments, capsules and inhalers, ...